Coamplification of prostate stem cell antigen (PSCA) and MYC in locally advanced prostate cancer

Genes Chromosomes and Cancer

Volumn 27, Issue 1, 2000, Pages 95-103

  Reiter, Robert E ^a,f   Sato, Issei ^b   Thomas, George ^c   Qian, Junqi ^b   Gu, Zhennan ^a   Watabe, Tetsuro ^a   Loda, Massimo ^d,e   Jenkins, Robert B ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MAYO CLINIC   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL ANTIGEN; CELL SURFACE MARKER; MONOCLONAL ANTIBODY;

ANTIGEN PRESENTATION; ARTICLE; CANCER GROWTH; CHROMOSOME 8Q; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE MAPPING; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; ONCOGENE; PRIORITY JOURNAL; PROSTATE CANCER;

ANTIGENS, NEOPLASM; CENTROMERE; CHROMOSOME MAPPING; CHROMOSOMES, HUMAN, PAIR 8; DNA PROBES; DNA, NEOPLASM; GENE AMPLIFICATION; GENE DOSAGE; GENES, MYC; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MEMBRANE GLYCOPROTEINS; NEOPLASM PROTEINS; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 0033991344     PISSN: 10452257     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2264(200001)27:1<95::AID-GCC12>3.0.CO;2-3     Document Type: Article

References (24)

1. Alers JC, Krijtenburg PJ, Rosenberg C, Hop WC, Verkerk AM, Schroder FH, van der Kwast TH, Bosman FT, van Dekken H. 1997. Interphase cytogenetics of prostatic tumor progression: specific chromosomal abnormalities are involved in metastasis to the bone. Lab Invest 77:437-448.
2. Bova GS, Isaacs WB. 1996. Review of allelic loss and gain in prostate cancer. World J Urol 14:338-346.
3. Bubendorf L, Kononen J, Koivisto P, Schraml P, Moch H, Gasser TC, Willi N, Mihatsch MJ, Sauter G, Kallioniemi OP. 1999. Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. Cancer Res 59:803-806.
4. Buttyan R, Sawczuk IS, Benson MC, Siegal JD, Olsson C. 1987. Enhanced expression of the c-myc protooncogene in high-grade human prostate cancers. Prostate 11:327-337.
5. Cher ML, MacGrogan D, Bookstein R, Brown JA, Jenkins RB, Jensen RH. 1994. Comparative genomic hybridization, allelic imbalance, and fluorescence in situ hybridization on chromosome 8 in prostate cancer. Genes Chromosomes Cancer 11:153-162.
6. Cher ML, Bova GS, Moore DH, Small EJ, Carroll PR, Pin SS, Epstein JI, Isaacs WB, Jensen RH. 1996. Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping. Cancer Res 56:3091-3102.
7. Disis ML, Cheever MA. 1997. HER-2/neu protein: a target for antigen-specific immunotherapy of human cancer. Adv Cancer Res 71:343-371.
8. Fleming WH, Hamel A, MacDonald R, Ramsey E, Pettigrew NM, Johnston B, Dodd JG, Matusik RJ. 1986. Expression of the c-myc protooncogene in human prostatic carcinoma and benign prostatic hyperplasia. Cancer Res 46:1535-1538.
9. Gao CL, Dean RC, Pinto A, Mooneyhan R, Connelly RR, McLeod, DG, Srivastava S, Moul JW. 1999. Detection of circulating prostate specific antigen expressing prostatic cells in the bone marrow of radical prostatectomy patients by sensitive reverse transcriptase polymerase chain reaction. J Urol 161:1070-1076.
10. Gu Z, Thomas G, Shintaku P, Yamashiro J, Said J, Loda M, Reiter RE. 1999. Monoclonal antibodies against prostate stem cell antigen detect high levels of PSCA expression in prostate cancer bone metastases. J Urol 161:126A.
11. 0 prostate cancer. Genes Chromosomes Cancer 21:131-143.
12. Jenkins RB, Qian J, Lieber MM, Bostwick DG. 1997. Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluoresence in situ hybridization. Cancer Res 57:524-531.
13. Kokontis J, Takakura K, Hay N, Liao S. 1994. Increased androgen receptor activity and altered c-myc expression in prostate cancer cells after long-term androgen deprivation. Cancer Res 54:1566-1573.
14. Magi-Galluzzi C, Mishra R, Fiorentino M, Montironi R, Yao H, Capodieci P, Wishnow K, Kaplan I, Stork PJS, Loda M. 1997. Mitogen-activated protein kinase phosphatase 1 is overexpressed in prostate cancers and is inversely related to apoptosis. Lab Invest 76:37-43.
15. Nupponen NN, Kakkola L, Koivisto P, Visakorpi T. 1998. Genetic alterations in hormone-refractory recurrent prostate carcinomas. Am J Pathol 153:141-148.
16. Reiter R, Gu Z, Watabe T, Thomas G, Szigeti K, Davis E, Wahl M, Nisitani S, Yamashiro J, Le Beau M, Loda M, Witte O. 1998. Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci USA 95:1735-1740.
17. 0 prostate carcinoma. J Urol 161:60A.
18. Steiner MS, Anthony CT, Lu Y, Holt JT. 1998. Antisense c-myc retroviral vector suppresses established human prostate cancer. Hum Gene Ther 9:747-755.
19. Takahashi S, Qian J, Brown JA, Alcaraz A, Bostwick DG, Lieber MM, Jenkins RB. 1994. Potential markers of prostate cancr aggressiveness detected by fluorescence in situ hybridization in needle biopsies. Cancer Res 54:3574-3579.
20. Thompson TC, Southgate J, Kitchener G, Land H. 1989. Multistage carcinogenesis induced by ras and myc oncogenes in a reconstituted organ. Cell 56:917-930.
21. Van Den Berg C, Guan XY, Von Hoff D, Jenkins RB, Bittner K, Griffin C, Kallioniemi O, Visakorpi T, McGill B, Herath J. 1995. DNA sequence amplification in human prostate cancer identified by chromosome microdissection: potential prognostic implications. Clin Cancer Res 1:11-18.
22. Visakorpi, T, Kallioniemi AH, Syvanen AC, Hyytinen ER, Karhu R, Tammela T, Isola JJ, Kallioniemi OP. 1995. Genetic changes in primary and recurrent prostate cancer by comparative genomic hybridization. Cancer Res 55:342-347.
23. Vocke C, Pozzatti RO, Bostwick DG, Florence CD, Jennings SB, Strup SE, Duray PH, Liotta LA, Emmert-Buck MR, Linehan WM. 1996. Analysis of 99 microdissected prostate carcinomas reveals a high frequency of allelic loss on chromosome 8p12-21. Cancer Res 56:2411-2416.
24. Whang YE, Wu X, Suzuki H, Reiter RE, Tran C, Vessella RL, Said JW, Isaacs WB, Sawyers CL. 1998. Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc Natl Acad Sci USA 95:5246-5450.